Enclomiphene citrate for the treatment of secondary male hypogonadism. (23rd July 2016)

• Record Type: Journal Article
• Authors: Rodriguez, Katherine M.; Pastuszak, Alexander W.; Lipshultz, Larry I.
• Is Part Of: Expert opinion on pharmacotherapy. Volume 17:Number 11(2016)
• Page Start: 1561
• Page End: 1567
• Publication Date: 2016-07-23
• Subjects: Hypogonadism -- testosterone -- enclomiphene citrate -- selective estrogen receptor modulator; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2016.1204294
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction : Hypogonadism is a growing concern in an aging male population. Historically treated using exogenous testosterone, concerns about possible adverse effects of testosterone have led physicians to seek alternative treatment approaches. Areas covered : Enclomiphene citrate is the trans isomer of clomiphene citrate, a non-steroidal estrogen receptor antagonist that is FDA-approved for the treatment of ovarian dysfunction in women. Clomiphene citrate has also been used off-label for many years to treat secondary male hypogonadism, particularly in the setting of male infertility. Here we review the literature examining the efficacy and safety of enclomiphene citrate in the setting of androgen deficiency. Expert opinion : Initial results support the conclusion that enclomiphene citrate increases serum testosterone levels by raising luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels, without negatively impacting semen parameters. The ability to treat testosterone deficiency in men while maintaining fertility supports a role for enclomiphene citrate in the treatment of men in whom testosterone therapy is not a suitable option.